a3879j
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of April 2020
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc
(the 'Company')
Annual General Meeting 2020 - Change of Arrangements
The Company published its Notice of Annual General Meeting 2020
('AGM Notice') on 23 March 2020 in respect of its Annual General
Meeting ('AGM') to be held on Wednesday 6 May 2020 at
2.30pm. In response to the current COVID-19 crisis, the UK
Government has since then established stay at home measures
prohibiting, amongst other things, public gatherings of more than
two people.
In light of these measures the AGM will be run as a closed meeting
and shareholders will not be able to attend in person. Shareholders
attempting to attend the AGM will be refused
entry. We hope that you
understand that we are taking these steps to protect our
shareholders, employees and the Board and as a result to enable the
Company to continue to focus on providing healthcare to patients in
need.
We will make arrangements such that the legal requirements to hold
the meeting can be satisfied through the attendance of two Company
director shareholders and/or employee shareholders. The AGM will
now be held at 980 Great West Road, Brentford, Middlesex TW8 9GS
(which is the Company's registered office) and not at the Sofitel
at Heathrow Airport. The time and date of the AGM remain as 2.30pm
on Wednesday 6 May 2020 and the business to be conducted remains as
set out in the AGM Notice.
The outcome of the resolutions will as usual be determined by
shareholder vote based on the proxy votes we
receive. Shareholders are strongly
encouraged to vote by proxy on the resolutions contained in the AGM
Notice. Given the
restrictions on attendance, shareholders are encouraged to appoint
the "Chairman of the Meeting" as their proxy rather than another
person who will not be permitted to attend the meeting. If any
shareholders have already submitted a Proxy Form appointing someone
other than the "Chairman of the Meeting", they are encouraged to
contact our registrar, Equiniti, as soon as possible on 0371 384
2991 (in the UK) or + 44 (0)121 415 7067 (outside the UK) to change
their proxy appointment to the "Chairman of the
Meeting".
Shareholders may appoint a proxy by completing and returning the
Proxy Form that was sent with the AGM Notice. Alternatively, a
proxy may be appointed electronically via www.shareview.co.uk, www.sharevote.co.uk or,
if shares are held in CREST, via the CREST
system. To ensure
votes are counted at the AGM, proxy appointments must reach
Equiniti by 2.30pm on Monday 4 May 2020.
Participants in the Company's UK Corporate Sponsored Nominee
service may exercise their votes through Equiniti by using the Form
of Direction that was sent with the AGM Notice. Alternatively, they
may exercise their votes electronically
via www.sharevote.co.uk.
Please note that such voting instructions must be received by
5.00pm on Wednesday 29 April 2020.
Any holder of the Company's shares through another nominee service,
should contact the nominee service provider regarding the process
for appointing a proxy. The deadline for this is likely to be much
earlier than Monday 4 May 2020.
All valid proxy appointments (whether submitted electronically or
in hard copy form) will be included in the poll to be taken at the
AGM. The results of the poll will be announced to the London Stock
Exchange and placed on our website, in the usual way, as soon as
practicable after the conclusion of the AGM.
The Board believes that the resolutions contained in the AGM Notice
continue to be in the best interests of the Company and its
shareholders as a whole and recommends that you vote in favour of
them.
Should a shareholder have a question that they would have raised at
the AGM, we ask that they send it by email
to company.secretary@gsk.com.
Answers to questions will be published on our website following the
AGM.
This situation is constantly evolving and the UK Government may
change the current restrictions or implement further measures
during the affected period. Shareholder engagement is important to
us even in these exceptional times. Although the restrictions mean
that we will not be able to hold our AGM in the usual way, we would
like to ensure that we can still respond to questions. Shareholders
should continue to monitor our website at www.gsk.com/en-gb/investors/shareholder-information/annual-general-meeting/ and
London Stock Exchange announcements for any updates regarding the
AGM. Alternatively, shareholders can contact Equiniti for updated
information (please see above for Equiniti's contact
details).
The Board would like to take this opportunity to thank all
shareholders for their continued support and understanding in these
exceptional circumstances and wish them well during this time. We
will return to full shareholder engagement as soon as
feasible.
V A Whyte
Company Secretary
9 April 2020
GSK - one
of the world's leading research-based pharmaceutical and healthcare
companies - is committed to improving the quality of human life by
enabling people to do more, feel better and live longer. For
further information please visit http://www.gsk.com.
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such
factors include, but are not limited to, those described under Item
3.D 'Principal risks and uncertainties' in the Company's Annual
Report on Form 20-F for 2019. GSK also refers investors to the
cautionary statement on the inside back cover of the Annual Report
2019.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: April
09, 2020
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|